id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-324666-fvk72o0p	Alharbi, Musa	Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib	2020-06-30		.txt	text/plain	2049	122	42	This case study demonstrates that first-line treatment of a neurotrophic receptor tyrosine kinase (NTRK) fusion-positive infantile glioblastoma with larotrectinib, an NTRK inhibitor (NTRKi), was a safe and effective way to achieve tumor regression in our patient. Follow-up MRI was performed 8 weeks after larotrectinib treatment and showed significant tumor regression, indicating a positive response to treatment with no reported adverse effects. Given that larotrectinib (Vitrakvi; Bayer, Whippany, NJ), an oral TRK inhibitor, has been approved for treatment of advanced tumors in adult and pediatric patients with NTRK gene fusions, 1 Licensed under the Creative Commons Attribution 4.0 License twice a day]) as a first-line therapy as a result of its convenience of administration, particularly in liquid formulations. Larotrectinib is a potent and selective inhibitor of all 3 TRKs, producing potent and well-tolerated responses in adult and pediatric patients with NTRK-rearranged tumors, with sustained tumor regression in .	./cache/cord-324666-fvk72o0p.txt	./txt/cord-324666-fvk72o0p.txt